WO2000078359A3 - Compositions for treating chemotherapy-resistant tumor cells - Google Patents

Compositions for treating chemotherapy-resistant tumor cells Download PDF

Info

Publication number
WO2000078359A3
WO2000078359A3 PCT/US2000/016955 US0016955W WO0078359A3 WO 2000078359 A3 WO2000078359 A3 WO 2000078359A3 US 0016955 W US0016955 W US 0016955W WO 0078359 A3 WO0078359 A3 WO 0078359A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tumor cells
resistant tumor
treating chemotherapy
chemotherapy
Prior art date
Application number
PCT/US2000/016955
Other languages
French (fr)
Other versions
WO2000078359A2 (en
Inventor
George Tuszynski
Taffy Williams
Paul Actor
Original Assignee
George Tuszynski
Taffy Williams
Paul Actor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by George Tuszynski, Taffy Williams, Paul Actor filed Critical George Tuszynski
Priority to AU54981/00A priority Critical patent/AU5498100A/en
Publication of WO2000078359A2 publication Critical patent/WO2000078359A2/en
Publication of WO2000078359A3 publication Critical patent/WO2000078359A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and compositions for treating cancer and chemotherapy-resistant cancers comprising a chemotherapeutic agent conjugated to or coadministered with a peptide.
PCT/US2000/016955 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells WO2000078359A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU54981/00A AU5498100A (en) 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14031099P 1999-06-21 1999-06-21
US60/140,310 1999-06-21

Publications (2)

Publication Number Publication Date
WO2000078359A2 WO2000078359A2 (en) 2000-12-28
WO2000078359A3 true WO2000078359A3 (en) 2002-01-24

Family

ID=22490672

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016955 WO2000078359A2 (en) 1999-06-21 2000-06-21 Compositions for treating chemotherapy-resistant tumor cells

Country Status (2)

Country Link
AU (1) AU5498100A (en)
WO (1) WO2000078359A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311892B2 (en) 2001-10-26 2007-12-25 The Uab Research Foundation Multidrug multiligand conjugates for targeted drug delivery

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443404A1 (en) * 1990-02-22 1991-08-28 W.R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin
EP0478101A2 (en) * 1990-09-24 1992-04-01 W.R. Grace & Co.-Conn. Therapeutic use of peptides having thrombospondin-like activity
WO1992017499A1 (en) * 1991-04-08 1992-10-15 Cornell Research Foundation, Inc. A unique hexapeptide derived from thrombospondin and its uses
EP0578342A2 (en) * 1992-05-14 1994-01-12 W.R. Grace & Co.-Conn. Purification and characterization of a CSVTCG-specific tumor cell adhesion receptor
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
WO1998035688A1 (en) * 1997-02-13 1998-08-20 Storz Instrument Company Method for destroying retinal pigment epithelial cells
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0443404A1 (en) * 1990-02-22 1991-08-28 W.R. Grace & Co.-Conn. Peptide fragments and analogs of thrombospondin
EP0478101A2 (en) * 1990-09-24 1992-04-01 W.R. Grace & Co.-Conn. Therapeutic use of peptides having thrombospondin-like activity
WO1992017499A1 (en) * 1991-04-08 1992-10-15 Cornell Research Foundation, Inc. A unique hexapeptide derived from thrombospondin and its uses
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
EP0578342A2 (en) * 1992-05-14 1994-01-12 W.R. Grace & Co.-Conn. Purification and characterization of a CSVTCG-specific tumor cell adhesion receptor
WO1998035688A1 (en) * 1997-02-13 1998-08-20 Storz Instrument Company Method for destroying retinal pigment epithelial cells
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor

Also Published As

Publication number Publication date
AU5498100A (en) 2001-01-09
WO2000078359A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO2002066019A3 (en) Cancer treatment
AU1656501A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
AU2001253140A1 (en) Tumor markers in ovarian cancer
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
AU2003293194A1 (en) Compositions and methods for treating prostate cancer
MXPA02010866A (en) Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy.
HK1024876A1 (en) Conjugates useful in the treatment of prostate cancer
AU2002335640A1 (en) Gleason grade 4/5 prostate cancer genes
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
AU2002341749A1 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
MXPA02005045A (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer.
AU8026300A (en) Sodd gene expression in cancer
WO2000078359A3 (en) Compositions for treating chemotherapy-resistant tumor cells
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
WO2000040752A3 (en) Cancer associated genes and their products
AU2506499A (en) Cea/nca-based differentiation cancer therapy
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU4452900A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001247560A1 (en) Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
AU4598100A (en) Treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP